GILD/ABBV/ENTA—The pricing is likely to vary on a country-by-country basis within the EU—and even among the top-5 countries that comprise about 2/3 of EU drug sales. It may take a year or two until we know how these market dynamics will play out.
In any event, things are off to a good start—ENTA is green as I'm typing :- )
Market Data 
Markets 
AI
